Madrigal Pharmaceuticals, Inc. has entered an exclusive global license agreement with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist and orforglipron derivative. Madrigal aims to begin clinical development of SYH2086 in the first half of 2026.
Bill Sibold, CEO of Madrigal, highlighted the deal’s alignment with the company’s long-term strategy to lead in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). “A combination of Rezdiffra, our approved therapy, and SYH2086 could offer a best-in-class oral treatment for MASH patients,” he said.
David Soergel, Chief Medical Officer at Madrigal, emphasized the clinical rationale for combining Rezdiffra with an oral GLP-1. He noted that the weight loss benefits of GLP-1 therapies complement Rezdiffra’s effects on fibrosis and lipid reduction, potentially enhancing efficacy and tolerability in a once-daily pill. Data from the Phase 3 MAESTRO-NASH trial showed that modest weight loss improved Rezdiffra’s antifibrotic benefits, supporting the potential of this combination approach.
Dongchen Cai, Chairman of CSPC, expressed confidence that Madrigal’s expertise in MASH treatment and commercial capabilities will help realize SYH2086’s full potential to benefit patients globally.
This licensing agreement expands Madrigal’s pipeline and strengthens its position in developing innovative therapies for liver disease.